Testing pozelimab safety in young children with CHAPLE disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests if pozelimab is safe for children aged 1 to 5 with CHAPLE disease, a rare condition that causes swelling, blood clots, and protein loss. If your child has active CHAPLE disease, this study may offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 5 years old.
- Your child must have a confirmed diagnosis of CD55-deficient CHAPLE disease.
- Your child must have active CHAPLE disease symptoms (like swelling, stomach problems, or protein loss).
- You must be willing to bring your child to clinic visits and follow study procedures.
- Your child must get the full series of meningococcal vaccines as required by the study.
- Your child cannot have had a meningococcal infection before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (pozelimab and cemdisiran) for adults with PNH whose current treatment (eculizumab, ravulizumab, or crovalimab) isn't controlling their symptoms well. It aims to see if the combination reduces red blood cell breakdown and improves blood counts.
This trial is testing an experimental drug (ION356) given by a lumbar puncture to see if it is safe and how it works in boys with Pelizaeus Merzbacher disease (PMD). The drug is designed to target the genetic cause of PMD.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests an experimental immunotherapy (PA3-17) designed to target and kill cancer cells that carry the CD7 marker in children and teens with T-cell leukemia or lymphoma that has returned or is hard to treat. It aims to see if the treatment is safe and effective at the best dose.
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
This Phase 2 study tests alpelisib in children and adults with MCAP, a condition caused by a specific PIK3CA gene mutation. The goal is to see if the treatment is effective and safe, while carefully monitoring blood sugar and organ function.
Hear when a new CHAPLE Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.